Monopar Therapeutics

Focus: Monopar Therapeutics is an oncology-focused pharmaceutical company specializing in small molecules and radiopharmaceutical imaging agents, based in Wilmette, Illinois with a lean operational footprint.

Oncology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Monopar Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Monopar Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

6 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

MNPR-101-DFO*-89Zr

Cancer

N/A

Clinical Trials (1)

NCT06980506MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

N/A

Help build intelligence for Monopar Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage focus on radiopharmaceuticals and targeted oncology—emerging modality with significant differentiation potential in precision medicine
Diversified pipeline across radiotherapy, chemotherapy, and supportive care (6 active programs spanning Phase 1–Phase 3) offers exposure to multiple therapeutic approaches
Specialized expertise in small molecules and radiopharmaceutical imaging positions scientists at the intersection of oncology innovation and diagnostic advancement

Watch Out For

No active job openings reported and minimal transparency on headcount, funding, or revenue—suggests very early stage or potential financial constraints
Pipeline programs remain early-stage (predominantly Phase 1) with no approved products; limited near-term clinical validation or commercial traction
Lack of public financial, hiring, and patent cliff data raises questions about company stability, growth trajectory, and career development infrastructure

Generated by Claude from Monopar Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

MNPR-101-PCTA-177Lu

Cancer

N/A

Clinical Trials (1)

NCT06980519MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

N/A

MNPR-101-PCTA-177Lu

Solid Tumor, Adult

Phase 1

Clinical Trials (1)

NCT06617169Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors

Phase 1